Navigation Links
Parkinson's Disease Treatment Pipeline is Likely to Meet Many Unmet Needs, says GBI Research

LONDON, January 12, 2016 /PRNewswire/ --

The treatment pipeline for Parkinson's disease offers a markedly more promising landscape from the current market, says GBI Research.

Analysis from business intelligence provider GBI Research - Frontier Pharma: Parkinson's Disease - Identifying and Commercializing First-in-Class Innovation - states that the current Parkinson's disease treatment market relies on neuromodulators, and although symptoms may be eased, there is not an agent that has demonstrated neuroprotective properties to prevent or at least significantly slow neuronal cell death.

The pipeline for Parkinson's disease, however, is highly active, consisting of 365 programs across all stages of development, and a diverse range of molecular targets. For a complimentary sample of this research, please visit the GBI Research website.

Analyst Angel Wong: "The Parkinson's disease treatment pipeline is characterized by a high level of innovation compared to the central nervous system segment and the industry as a whole, with 43% of all pipeline programs with disclosed molecular targets being first-in-class.

"While neuromodulators remain dominant in the pipeline, there are a number of targets which address different pathogenic mechanisms underlying neurodegeneration in Parkinson's disease. This demonstrates a shift from traditional symptomatic treatments to disease-modifying therapies."

The analyst adds that as the majority of potentially disease-modifying treatments are in the early stages of development, they are expected to fulfill a huge unmet need in the Parkinson's disease market in the long term.  

GBI Research's report also states that there are 94 first-in-class products available for strategic consolidations, meaning a vast number of investment opportunities are available for licensing or co-development deals in Parkinson's disease.

Wong explains: "There is substantial focus on early-stage collaboration in Parkinson's disease, especially for first-in-class products. This is predominantly driven by growing unmet needs, the current lack of disease-modifying therapies and a desire for risk-sharing.

"Several first-in-class products have demonstrated promising preclinical evidence, and have significant potential to become game-changing products, representing high-reward investments."

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-161-359-5817

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook | LinkedIn | Twitter

Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
2. Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
3. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
4. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
7. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Investigational New Drug Application Cleared by FDA for OMS824 in Huntingtons Disease
10. Health Diagnostic Laboratory, Inc. Announces Diabetes Prevention & Management Panel for Early Detection and Treatment of Disease
11. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
Post Your Comments:
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):